Vir Biotechnology, Inc.

9.19 USD
+0.03 (+0.33%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Vir Biotechnology, Inc. stock is down -14.35% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 June’s closed higher than May. In the last 2 Unusual Options Trades, there were 1 CALL, 1 PUT. 67% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
28 May 19:57 19 Jul, 2024 12.50 CALL 649 1333
29 May 18:23 19 Jul, 2024 10.00 PUT 450 88

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs, for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health.

  • Morgan Stanley
    Thu Jun 6, 09:11
  • HC Wainwright & Co.
    Wed Jun 5, 12:19
  • Needham
    Wed Jun 5, 12:16